Brokerages Set Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) PT at $12.63

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) have been assigned a consensus recommendation of “Buy” from the nine brokerages that are currently covering the firm, Marketbeat reports. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $12.6250.

CATX has been the topic of a number of research analyst reports. Wedbush reissued an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a report on Tuesday, May 5th. HC Wainwright raised their price objective on shares of Perspective Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Monday, March 23rd. Truist Financial set a $12.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, March 17th. Piper Sandler began coverage on shares of Perspective Therapeutics in a research report on Thursday, February 19th. They set an “overweight” rating and a $16.00 price objective on the stock. Finally, BTIG Research restated a “buy” rating and set a $14.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, March 17th.

Perspective Therapeutics Price Performance

Shares of Perspective Therapeutics stock opened at $3.85 on Friday. Perspective Therapeutics has a 12-month low of $1.96 and a 12-month high of $6.16. The company’s 50-day moving average price is $4.38 and its 200-day moving average price is $3.61.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. The firm had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.16 million. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 42.33%. Equities analysts forecast that Perspective Therapeutics will post -1.15 earnings per share for the current year.

Institutional Trading of Perspective Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. raised its position in shares of Perspective Therapeutics by 184.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock valued at $29,000 after buying an additional 5,475 shares in the last quarter. Aigen Investment Management LP purchased a new position in shares of Perspective Therapeutics during the fourth quarter worth approximately $28,000. nVerses Capital LLC purchased a new position in shares of Perspective Therapeutics during the fourth quarter worth approximately $31,000. Abel Hall LLC purchased a new position in shares of Perspective Therapeutics during the first quarter worth approximately $49,000. Finally, Engineers Gate Manager LP purchased a new position in shares of Perspective Therapeutics during the fourth quarter worth approximately $35,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.